Evrópusambandið - króatíska - EMA (European Medicines Agency)

merck sharp & dohme b.v. - efavirenz - hiv infekcije - antivirusni lijekovi za sustavnu uporabu - stocrin je indiciran u antivirusnom kombiniranom tretmanu odraslih, adolescenata i djece starijih od tri godine starijih od ljudske imunodeficijencije-1 (hiv-1). Стокрин nisu bili pravilno istražena u bolesnika s uznapredovalom faze infekcije hiv-om, a upravo je u bolesnika s razinom cd4 < 50 ćelija/mm3, ili nakon neuspjeha протеаза-inhibitora (pi)-sadrže sheme. iako je cross-otpornost эфавиренза sa ip nije bio registriran, trenutno nema dovoljno podataka o efikasnosti kasniju upotrebu pi na temelju kombinirane terapije neučinkovitosti sheme sadrže Стокрин.

Evrópusambandið - króatíska - EMA (European Medicines Agency)

bial portela & companhia s.a. - opicapone - parkinsonova bolest - antiparkinsonski lijekovi - ontilyv is indicated as adjunctive therapy to preparations of levodopa/ dopa decarboxylase inhibitors (ddci) in adult patients with parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.

Evrópusambandið - króatíska - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumab, relatlimab - melanoma - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.

Evrópusambandið - króatíska - EMA (European Medicines Agency)

novartis europharm limited - amlodipin, валсартан, hidroklorotiazid - hipertenzija - antagonisti angiotenzina ii u kombinaciji, agenti koji djeluju na ренин-ангиотензиновую sustav, antagonisti angiotenzina ii i antagonisti kalcija - liječenje esencijalne hipertenzije kao zamjena terapija u odraslih bolesnika čiji krvni tlak odgovarajuće kontroliran na kombinaciji amlodipin, valsartan i hidroklorotiazid (hct), uzeti kao tri pojedinačnih formulacije ili je dvojan-komponenta i pojedinačnih formulacija.

Evrópusambandið - króatíska - EMA (European Medicines Agency)

samsung bioepis nl b.v. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastična sredstva - aybintio in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. aybintio in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. za daljnje informacije o stanju čovjeka epidermalnog faktora rasta receptora 2 (her2), molimo pogledajte odjeljak 5. 1 of the smpc. aybintio in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracyclinecontaining regimens in the adjuvant setting within the last 12 months should be excluded from treatment with aybintio in combination with capecitabine. dodatne informacije o statusu her2 potražite u odjeljku 5. 1 of the smpc. aybintio, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. aybintio, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. 1 of the smpc). aybintio in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. aybintio, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. 1 of the smpc). aybintio, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. aybintio, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. 1 of the smpc). aybintio, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5. 1 of the smpc).

Evrópusambandið - króatíska - EMA (European Medicines Agency)

samsung bioepis nl b.v. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastična sredstva - onbevzi in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. onbevzi in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. za daljnje informacije o stanju čovjeka epidermalnog faktora rasta receptora 2 (her2), molimo pogledajte odjeljak 5. onbevzi in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with onbevzi in combination with capecitabine. dodatne informacije o statusu her2 potražite u odjeljku 5. onbevzi, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. onbevzi, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations. onbevzi in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. onbevzi, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer. onbevzi, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. onbevzi, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. onbevzi, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

Króatía - króatíska - HALMED (Agencija za lijekove i medicinske proizvode)

belupo lijekovi i kozmetika d.d., ulica danica 5, koprivnica - melissae mjestu folii extractum siccum, valerijana extractum siccum hydroalcoholicum, passiflorae herbae extractum siccum - obložena tableta - 112,5 mg + 125 mg + 80 mg - urbroj: svaka obložena tableta sadrži: 112,5 mg ekstrakta (kao suhi ekstrakt) iz melissa officinalis l., folium (matičnjakov list) (4-6:1); ekstrakcijsko otapalo: metanol 30% v/v, 125 mg ekstrakta (kao suhi ekstrakt) iz valeriana officinalis l., radix (odoljenov korijen) (3-6:1); ekstrakcijsko otapalo: etanol 70% v/v, 80 mg ekstrakta (kao suhi ekstrakt) iz passiflora incarnata l., herba (pasiflorova zelen) (5-7:1); ekstrakcijsko otapalo: etanol 50% v/v.

Bosnía og Hersegóvína - króatíska - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

zentiva pharma d.o.o. - Сухи ekstrakt korijena odoljena, Сухи ekstrakt pasiflore - kapsula, tvrda - 140 mg/1 kapsula+ 175 mg/1 kapsula - 1 kapsula, tvrda sadrži: 140 mg ekstrakta suhog ekstrakta korijena valerijane (valeriana officinalis l., radix, ekstraktum siccum), (46:1) i 175 mg suhog ekstrakta pasiflore (passiflora incarnata l. herba), (57:1)

Bosnía og Hersegóvína - króatíska - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

viennapharm d.o.o. - kalcijumfosfat, kalcijumkarbonat, kamilica, magnezijumfosfat, željezofosfat - pilule - 3.8 mg/1 g+ 3.8 mg/1 g+ 0.8 mg/1 g+ 0.8 mg/1 g+ 0.8 mg/1 g - 1 g pilula sadrži: chamomila recutita d6 3,8 mg + calcium phosphoricum d12 3,8 mg + magnesium phosphoricum c6 0,8 mg + calcium carbonicum hahnemanni dil. c8 0,8 mg + ferrum phosphoricum c8 0,8 mg

Evrópusambandið - króatíska - EMA (European Medicines Agency)

viatris healthcare limited - fenofibrate, simvastatin - dislipidemije - sredstva za modifikaciju lipida - cholib je indiciran kao dodatna terapija dijeti i tjelovježbi u odraslih bolesnika visokim s mješovitim dislipidemijom za smanjenje triglicerida i povećanje razine hdl c kad ldl c razinama adekvatno upravlja pomoću odgovarajuće doze monoterapije simvastatinom.